Zimmer Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Zimmer Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40,000	Closed	-$420K	–	178
2024 Q4	$420K	Buy	+40,000	New	+$486K	0.01%	144

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zimmer Partners's AVDL Position: Q1 2025 in Review

Zimmer Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 40,000 shares — an estimated $420K sold.

Zimmer Partners first reported a position in AVDL in Q4 2024 and held it in 1 quarter. The position peaked at $420K in Q4 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

Zimmer Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Zimmer Partners sold 40,000 Avadel Pharmaceuticals shares in Q1 2025, an estimated $420K.
Zimmer Partners first reported a position in Avadel Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Zimmer Partners's Avadel Pharmaceuticals position peaked at $420K in Q4 2024.
175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on Zimmer Partners's 13F filing for Q1 2025, filed 15 May 2025.